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FOLLOWING Borel's description of a new immunosuppressive agent, a fungal
cyclic peptide, Cyclosporin A (CyA), which had immunosuppressive action 1 a
number of experimental papers demonstrated that the agent was a potent
inhibitor of rejection of organ allografts in a variety of species 2, 3, 4, 5, 6, 7, 8.
Green and Allison 9 found that a short period of treatment with CyA given
to rabbits with renal allografts could be followed by prolonged acceptance of the
transplant and suggested that CyA might be eliminating clones of lymphocytes
reactive against the allograft in question. The mode of action of CyA is not
understood but there is agreeinent by independent workers that the agent is more
active against proliferating T-cells than other members of the lymphoid series 10,
11, 12. We have published two interim reports on a pilot study of CyA 13, 14
initially as the only immunosuppressive agent in human recipients of cadaveric
organ grafts. This study has now been in progress for two years. Fifty-eight
patients have received 65 cadaver organ grafts, 51 kidney grafts, eight segmental
vascularised pancreas grafts and six orthotopic liver allografts. The 58 patients
range in age from 2 to 59. Nineteen were over 50 years. Two renal allografts
were second transplants after the first had failed for technical reasons. The
remaining 62 organs were first grafts. All received organs mismatched for A and B
locus antigens. In most cases there were two or more mismatches. Details of DR
matching are not available. All but one of the 51 recipients with renal allografts
had previously been given blood transfusions. Six of the renal allograft recipients
also received segmental grafts of pancreas from the same donor. Six patients
received orthotopic liver grafts. One of these also had a segmental pancreatic
graft. One patient with rapidly progressive retinopathy and severely impaired
vision from insulindependent diabetes received a segmental pancreas allograft
alone. Of 51 patients who received renal allografts CyA was given at an initial
dose of 25 mg/kg/day in seven cases, 10 mg/kg/day in four cases and 17 mg/kg/
day in the remaining forty cases.
The tail and body of the pancreas vascularised from the splenic vessels were
transplanted into the right iliac fossa, according to the technique of Gleidman 15.
* Department of Pathology, University of Cambridge
* * Dialysis Unit, Addenbrooke's Hospital, Hills Road, Cambridge
Department of Biochemistry, University of Cambridge
.... Liver Unit, King's College Hospital, London
62The duct was injected with latex solution 6 based on the technique of- Dubernard
16. In seven cases a small window was cut in the peritoneum and the omentum
brought through the window and wrapped around the pancreas. In three
patients a distal splenic arteriovenous anastomosis was constructed to increase
the flow of blood through the splenic vessels following experimental studies on
the blood supply of pancreatic allografts in dogs 17.
The patients with orthotopic liver allografts received CyA 10 mg/kg/day
starting dose. CyA was given initially intramuscularly for the first two or three
days in all patients. Subsequently they were changed to an oral preparation.
RESULTS
Renal Grafts
Despite the most careful assessment of a new drug in animals, when it is first
used in patients the clinical course cannot be predicted and there may be
unexpected dangers. This has been the case with CyA and as certain undesirable
characteristics of the drug were observed in man so the protocol was modified.
The actuarial survival of functioning renal allografts in the whole series is shown
in Fig 1 18.
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The most serious side effect of Cyclosporin A, nephrotoxicity, became apparent
shortly after the trial commenced. There was impairment of renal function,
oliguria and sometimes anuria, with no light or electron microscopical changes
on renal biopsy to explain the toxic effects of the drug. Since a mild cellular
infiltrate was common in these biopsies, patients with any changes attributable
to an immune reaction were treated with other immunosuppressive agents and
63six patients were given Cytimun, a cyclophosphamide derivative, and steroids in
addition to CyA. Five of these patients died from infections and one of these was
found to have a jejunal lymphoma at post-mortem examination. Four of the
first 15 patients had been given prednisolone in addition to CyA for suspected
rejection. One of these patients died after four months from septicaemia with
pneumonitis and lymphoma in the lung, liver and lymph nodes. In this whole
series there were 13 deaths six of these were in the first fourteen cases, all dying
of sepsis. It was noted that four patients deliberately hydrated and given mannitol
in the perioperative phase had primary diuresis without signs of significant
nephrotoxicity from the CyA. It was therefore decided in May 1979 to change
the policy of management as follows. All renal allograft recipients would receive
17 mg/kg/day of CyA as an initial starting dose. This would be dropped slowly
according to renal function and eventually tailed down to as low a dose as would
maintain satisfactory allograft function. Only patients with kidneys that were
diuresing at 3 hours would be given CyA. Non-diuresing patients would be given
conventional immunosuppression. All patients would be deliberately hydrated
and given mannitol during the operation and postoperatively. If secondary anuria
occurred a renal biopsy would be performed. If this showed rejection the patient
would be given a course of steroids. The dose of steroids and timing of treatment
of rejection crises varied initially, but eventually was settled at a maximum of six
one gram doses of Solu-Medrone over 14 days. If rejection continued, the kidney
would be abandoned or the patient changed to conventional immunosuppressive
agents, Imuran and steroids.
The actuarial kidney allograft survival curve of 32 patients receiving kidneys
without.other organs, who were hydrated and given mannitol and managed
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64according to the proposal outlined above is shown in Figure 2. There were four
failures in these 32 patients, three of whom died:
(1) from a combination of secondary hyperparathyroidism and pneumocystic
infection in the lung,
(2) from lung sepsis and disseminated intravascular coagulation, septicaemia
and fungal abscesses. This patient had poor renal function and there were
hypertensive changes in the donor kidney at the time of transplantation.
(3) from haemorrhage from the inferior epigastric artery following renal
biopsy during an episode of impaired renal function, probably due to CyA
nephrotoxicity. The renal biopsy was normal.
Another patient in this group of 32 developed purulent bacterial sepsis around
the kidney and had an allograft nephrectomy and is now being maintained on
dialysis.
Four of the 32 patients have been changed to conventional immunosuppression,
between three weeks and five months after grafting. Renal function has varied
from normal to good, the highest serum creatinine in patients still receiving CyA
being 430 mg/ml and the lowest 60 in a 2 year old child.
Pancreas Grafts
Of the eight patients receiving pancreas allografts two died, one on the third
day from overhydration. The kidney had not responded to hydration and
mannitol. This patient had a cardiac arrest from fluid overload and both organs
were vascularised at the time of death. The second death was from pneumonia
after removal of the pancreas allograft, which had been rejected and was bleeding.
Subsequently, the kidney was rejected and the patient developed septicaemia.
One graft became infarcted due to primary vascular thrombosis, and the pancreas
was removed. This patient's kidney graft was rejected and also removed. He had
since been retransplanted with another kidney and is being treated with azathio-
prine and steroids and now has a functioning renal allograft. Five patients have
functioning pancreatic allografts and are not requiring insulin or steroids. Three
of these patients have kidney allografts, one a liver allograft; the fifth has only
a pancreas. It will require study over a number of years in patients with function-
ing allografts, to determine whether this form of treatment will prevent
progression of microangiopathy. The five patients have normoglycaemia and
good function of their additional allografts 19. Three of the patients had distal
splenic arteriovenous anastomoses constructed. Two of these pancreases are
functioning well. The third rejected the allograft and bled from the splenic vein.
Liver allografts
Of the six patients receiving liver allografts using CyA, one had a segmental
pancreatic allograft (see above) and is alive and well after nine months. Another
patient with a hepatoma has had recurrent hepatoma in the lungs excised. These
deposits were present at the time of operation but had not been detected
65preoperatively. She is still on CyA with good liver function. Two patients
developed renal failure in the early postoperative phase after liver grafting. Both
had been on the verge of renal failure prior to liver grafting. Both required
dialysis postoperatively. Renal function improved and in one case the immuno-
suppression was changed to azathioprine and steroids. This patient is alive and
well. The other patient had the CyA stopped because of the renal function
impairment. She developed progressive jaundice, which on biopsy was found to
be due to rejection of the liver, in which the intrahepatic bile duct epithelium
was severely damaged. She died from liver failure. Another patient required
Solu-Medrol pulses for rejection crises which were not controlled. The CyA was
stopped and she now receives Cytimun and prednisolone. This limited experience
of CyA in liver grafting shows that a dose of 10 mg/kg has an immunosuppressive
effect, but rejection crises have occurred. There has also been nephrotoxicity. We
have not observed hepatotoxicity in these patients but in the presence of rejection
of the liver, some of the hepatic functional impairment could have been due to
CyA.
COMPLICATIONS
Lymphomas
The three lymphomas in this series are the subject of a separate publication 20.
Two were found incidentally at postmortem examination in patients dying from
sepsis. The third case occurred in a patient who was not hydrated and did not
receive mannitol. The allograft was anuric and biopsy after a week showed mild
tubular necrosis. No other drug was added and there was diuresis from day 16.
Good renal function ensued. Three months after operation he developed a sore
throat and in retrospect from an analysis of titres of EB virus he probably had
an attack of acute mononucleosis at this time. A month later he developed weight
loss and dyspepsia. Endoscopy showed ulceration in the lesser curve of the
stomach and duodenum. Biopsy of the duodenal ulcer showed lymphoma. Gastro-
duodenal resection was performed in September 1979, five months after his
transplant and the CyA was reduced to a dose of 100 mg/day, approximately
1.5 mg/kg. He gained weight, felt well and went back to work. Seven months
after resection of the gastro-duodenal lymphoma and reduction of CyA dose his
renal function deteriorated and he became hypertensive. Biopsy showed changes
of acute cellular rejection, together with some scarring and atrophy of areas of
the renal parenchyma. The CyA was stopped and he was given azathioprine and
prednisolone and his hypertension was brought under control. His renal function
has now improved and there is no clinical evidence of recurrence of the lymp-
homa. It is well known that effective immunosuppression, particularly with agents
that impair T-cell function lead to a high incidence of lymphoma 21 22.
A relationship of lymphoma to viral infection and lack of T-cell control of
proliferating B-cells has been suggested 23. A further case similar to our own has
been reported in a patient with a renal allograft given CyA and steroids 24. The
hazards of lymphoma will remain with effective immunosuppression but in none
66of the 32 patients managed according to our revised protocol has lymphoma
occurred, so it may be possible to avoid a high incidence of lymphoma if CyA
is used correctly.
Mild impairment of liver function tests and fine tremor of the hands were
described as common in our previous reports, but with our recent modiflod
protocol of management these have been less frequent and not severe and the
incidence of infection has not been high. The increase in growth of fine hair on
the face and body does not usually bother patients greatly. The gum hypertrophy
can be annoying in some patients but is usually not an important disability.
Reactivation of virus infection and the development of de-novo virus infections
have occurred as with other immunosuppressive regimes 25.
There is no evidence of permanent structural damage to the kidneys in patients
treated with CyA. Some kidneys have had scarring on biopsy but this could well
be explained as being due to a combination of hypertension and previous rejection
episodes. Since CyA is acutely nephrotoxic it is possible that the drug could
aggravate structural changes due to other causes but there is no direct evidence
of this. One of the main clinical impressions is the rapid reversal of the nephro-
toxic effect when CyA dose is reduced or stopped.
Breast lumps
Two of our patients developed benign breast lumps after CyA treatment. One
patient had had previous dysplastic changes in the breast and developed a benign
fibroadenoma one year after grafting. Another patient treated only with CyA
developed a fibroadenoma which was resected, one year after grafting. Three
months later she developed lumps in both breasts and two fibroadenomata were
removed from the same breast as previously. The lump in the other breast was
not excised. The CyA dose was reduced to 2 mg/kg. Six weeks later renal
function rapidly deteriorated and a renal biopsy was performed. This was the
first renal biopsy this patient had had and the changes were of severe cellular
rejection with no scarring of the kidney, no chronic vascular changes and no
acute vasculitis. This patient had been treated with CyA for nearly two years
and there was no evidence of structural damage that could be attributed to the
drug. The acute rejection following reduction in the dose of CyA had the
appearances of an early unmodified cellular reaction. It has responded well to
conventional treatment with Imuran and steroids.
DISCUSSION
CyA has also been used in patients with marrow grafts for the treatment of
graft-versus-host disease 2f It has been found to be very effective in these
patients and none has developed a lymphoma 27. Other centres have started using
CyA in pilot studies with varying regimes, but to date there are no reports in the
literature. Based on our experience and in an attempt to prevent repeating errors
we have made, our conclusions would be as follows:
67Cyclosporin A is an extremely powerful immunosuppressive drug in man. We
would recommend that the agent be used initially as the sole immunosuppressive
drug. In patients receiving renal allografts at a dose of 17 mg/kg/day as a starting
dose, reducing the dose at 2 weeks dropping 2 mg/kg every month until a
maintenance dose of between 6 and 8 mg/kg/day is reached and staying at around
this dose provided that renal function is satisfactory. It is quite clear that if the
dose gets below 2 mg/kg/day acute rejection can occur, described in two patients
above. We believe that only patients with diuresing renal allografts should be
given CyA and if there is secondary anuria, biopsy should be performed. If this
shows rejection, up to six doses of Solu-Medrone should be given over a course of
two weeks. If these fail to control rejection, the patient should be changed to
azathioprine and steroids and CyA stopped. The need for continuing CyA in
man or changing to azathioprine and prednisolone argues strongly against the
suggestion that the drug acts by clonal deletion. Eight patients have been
switched from CyA to azathioprine and steroids with good function in their
allografts at present. Although two of our patients are continuing with CyA and
long-term prednisolone, we are trying to wean them slowly off the steroid. It is
our impression that CyA is better used alone than with long-term steroids. If CyA
and a short course of Solu-Medrol does not control rejection, we prefer to change
to azathioprine and prednisolone.
Of the patients changed to conventional therapy, two were changed because
CyA could not be continued at the high dose, in one case due to recurrent fibro-
adenomata and the other due to restricted lymphoma. The remainder were
changed because of failure to respond to one course of Solu-Medrone.
One liver recipient was changed because of acute renal failure, possibly
aggravated by CyA. A further patient, who rejected his kidney and pancreas,
following removal of the allografted organs received a second kidney transplant
and was treated with azathioprine and steroids with good function in his renal
graft.
Our early results with segmental pancreas allografting show that control of
diabetes can be achieved with CyA as an immunosuppressant. A two year old
child has been successfully transplanted with a kidney and although requiring
steroids for rejection, is now receiving only CyA. Previously it has been our
policy not to transplant young children because of the side effects of steroids.
Thirteen of our patients have never received steroids and have good allograft
function being treated only with CyA. Another 16 are not now receiving steroids
or any other immunosuppressive agent, apart from CyA. Out of 58 patients, 29
have not required long-term maintenance with steroids. This is a particularly
attractive feature of CyA. CyA being totally insoluble in water and aqueous
solvents requires administration in an oily solution. Absorption probably depends
on the presence of bile salts, and satisfactory transport mechanisms through the
gastro-intestinal wall. Absorption from intramuscular injection may be slow.
Impairment of liver function may prevent adequate absorption of the drug and
since the liver is probably responsible for most of the excretion of CyA, if the
drug is given parenterally liver damage may cause high blood levels of the drug.
68A proportion of CyA and its metabolites are excreted in the kidneys, therefore
impaired renal function could also result in high CyA blood levels (personal
communication Sandoz).
The pharmacokinetics of CyA in man have not been determined to a satis-
factory extent because of difficulty measuring the drug. Radioimmunoassay
techniques have been technically unsatisfactory; more consistent results are now
being obtained (personal communication Sandoz). It may well be that there are
marked individual variations in metabolism, absorption and excretion of the agent
and titration of blood levels will be the best way of administering the drug. Since
such developments in the use of the drug are not yet available, the question
arises whether there is sufficient knowledge and experience to justify continuing
use of CyA based on empirical observations and pilot studies. In the evolution
of the protocol of CyA management in our trial, we are now obtaining good
results and are able to transplant patients previously thought to be unsuitable,
namely those with insulin-dependent diabetes and children. We feel that there
is now sufficient information to mount a controlled trial of CyA based on the
above protocol, to compare it with conventional immunosuppression using
azathioprine and steroids.
We are most grateful to Sandoz for all their help in the pursuit of this work and to our
medical, scientific and nursing and technical colleagues at Cambridge and the Liver Unit,
King's College Hospital, London who have assisted in this difficult phase of drug assessment.
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